Please upgrade your browser.
Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial
Nivolumab, a programmed death-1 immune checkpoint inhibitor, demonstrated encouraging overall survival (OS) and manageable safety in previously treated patients (pts) with metastatic renal cell carcinoma (mRCC) in a randomized phase 2 dose-ranging trial (NCT01354431). Median OS was 18.2–25.5 months (Motzer RJ, et al. J Clin Oncol, 2014). As response patterns with immunotherapy differ from those with chemotherapy, some pts may benefit from continued treatment with immunotherapy after initial evidence of RECIST-defined progression (Wolchok JD, et al. Clin Cancer Res, 2009). We present efficacy and safety in a subset of pts who were treated with nivolumab beyond RECIST-defined progression to investigate the potential benefits of this treatment approach.
New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model has been validated for patients (pts) with mRCC in the second line TT setting. This model does not consider time from 1st to 2nd line therapy, tumor shrinkage during 1st line and tumor burden before 2nd line. We sought to investigate these factors in addition to IMDC ones.
News and information about clinical trials and the role of immunotherapy in the treatment of renal cancers.
Researchers have developed a promising titanium and gold based compound that destroys kidney cancer cells, while leaving normal cells unharmed.
The successful outcome means Opdivo is the first so-called immune checkpoint inhibitor drug to show an improvement in overall survival in patients with renal cell carcinoma (RCC), a common type of kidney cancer.
Investment—not good intentions—fuels high-risk research, and price controls will limit new therapies.
Following progression on first-line therapy, patients with renal cell carcinoma (RCC) often do not need to be hurried to second-line treatment, says David F. McDermott, MD. If there is existing disease that is not harming the patient, and the patient feels well, there is no reason to switch therapies, adds Eric Jonasch, MD.
Today's Penn State football news features a look at defensive coordinator Bob Shoop, who announced via Twitter Friday that every sack registered by the Nittany Lions defense will result in a $107 donation to help fight kidney cancer
The Young Investigator Award (YIA) is a one-year research grant totaling $50,000, paid in two equal installments to the awardee’s institution.
"The link between tobacco and cancer is widely known and readily accepted by the public but many are not yet fully convinced that healthy eating, regular exercise and not drinking alcohol can lower your cancer risk."
|Powered by NeonCRM|